Breaking News

Crucell Receives First Wyeth Biotech Orders

Crucell has received its first orders for the CMO agreement with NJ-based Wyeth Biotech. The agreement for formulation and filing of a vaccine was finalized at the end of 2005 and will have the first business impact for Crucell in 2007. The vaccine will be supplied from Crucell’s Swiss subsidiary.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters